(Q40467969)

20 September 2017

Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis. (English)

1 reference

20 September 2017

1

Slawomir Majewski

1 reference

20 September 2017

5

Stefania Jablonska

1 reference

20 September 2017

4

Bernd Benninghoff

1 reference

20 September 2017

Maria Marczak

2

1 reference

PubMed ID

15663652

20 September 2017

Beata Mlynarczyk

series ordinal

3

1 reference

20 September 2017

1 January 2005

1 reference

International Journal of Dermatology

20 September 2017

1 reference

20 September 2017

44

1 reference

20 September 2017

1

1 reference

20 September 2017

14-19

1 reference

Review Article Imiquimod applied topically: a novel immune response modifier and new class of drug

20 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02318.X

Imiquimod: a potential role in dermatology?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02318.X

Imiquimod: a cytokine inducer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02318.X

Effects of the immunomodulating agent R837 on acute and latent herpes simplex virus type 2 infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02318.X

Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02318.X

A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02318.X

Angiogenesis in cancer, vascular, rheumatoid and other disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02318.X

Molecular foundations of cancer: New targets for intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02318.X

Biological implications of macrophage infiltration in human tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02318.X

The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02318.X

Lymphocyte-induced angiogenesis: a quantitative and sensitive assay of the graft-vs.-host reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02318.X

Successful topical immunotherapy of bowenoid papulosis with imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02318.X

Successful treatment of anogenital Bowen's disease with the immunomodulator imiquimod, and monitoring of therapy by DNA image cytometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02318.X

Successful treatment of actinic keratosis with imiquimod cream 5%: a report of six cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02318.X

Clinical effect of imiquimod 5% cream in the treatment of actinic keratosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02318.X

Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: An open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02318.X

Imiquimod 5% cream in the treatment of Bowen's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02318.X

Bowen's disease (squamous cell carcinoma in situ) in immunosuppressed patients treated with imiquimod 5% cream and a cox inhibitor, sulindac: potential applications for this combination of immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02318.X

Topical imiquimod treatment of superficial and nodular basal cell carcinomas in patients affected by basal cell nevus syndrome: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02318.X

Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02318.X

Cloning of a new cytokine that induces IFN-gamma production by T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02318.X

In vivo antitumor effects of murine interferon-gamma-inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02318.X

Both E6 and E7 oncoproteins of human papillomavirus 16 inhibit IL-18-induced IFN-gamma production in human peripheral blood mononuclear and NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02318.X

Down modulation of IL-18 expression by human papillomavirus type 16 E6 oncogene via binding to IL-18.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02318.X

10.1111/J.1365-4632.2004.02318.X

21 January 2018

Identifiers

DOI

1 reference

20 September 2017

1 reference

PubMed ID

15663652